Abstract：
Approximately 30% of people with schizophrenia fail to respond to first-line antipsychotic treatment which impacts the burden of the disease. Treatment-resistant schizophrenia (TRS) denotes patients with failure to respond to at least two adequate trials of different antipsychotics. Clozapine is a unique drug approved for treating treatment-resistant schizophrenia, however 1/3 of patients fail to respond to clozapine. Even though different strategies have been proposed for treating clozapine-resistant schizophrenia, the evidence is very limited, unclear, and of poor quality. A formal literature search was conducted and then, panel members were asked to complete 35 questions addressing different aspects of TRS. A modified Delphi method was used to unify expert opinion and achieve consensus. The expert consensus in diagnostic and treatment of TRS is the result of experts from the main national scientific societies under the organization of the Argentine Association of Biological Psychiatric (AAPB). The consensus statement aims to guide on diagnosis and treatment.
摘要：
大约30％的精神分裂症患者对一线抗精神病药物治疗没有反应，这影响了疾病的负担。抗治疗精神分裂症（TRS）表示患者对至少两个不同抗精神病药的适当试验没有反应。氯氮平是一种被批准用于治疗难治性精神分裂症的独特药物，然而，1/3的患者对氯氮平无效。尽管已经提出了不同的策略来治疗氯氮平耐药的精神分裂症，证据非常有限,不清楚,质量差。进行了正式的文献检索，然后，小组成员被要求完成35个问题，涉及TRS的不同方面。采用改进的德尔菲法统一专家意见，达成共识。TRS诊断和治疗方面的专家共识是阿根廷生物精神病学协会（AAPB）组织下主要国家科学协会的专家的结果。共识声明旨在指导诊断和治疗。
